FMP
Meridian Bioscience, Inc.
VIVO
NASDAQ
Inactive Equity
Meridian Bioscience, Inc., a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for gastrointestinal and respiratory infectious diseases, and elevated blood lead levels worldwide. The company operates through Diagnostics and Life Science segments. The Diagnostics segment offers testing platforms, including real-time PCR amplification under the Revogene brand; isothermal DNA amplification under the Alethia brand; lateral flow immunoassay using fluorescent chemistry under the Curian brand; rapid immunoassay under the ImmunoCard and ImmunoCard STAT! brands; enzyme-linked immunoassays under the PREMIER brand; anodic stripping voltammetry under the LeadCare brands; and urea breath testing for H. pylori under the BreathID and BreathTek brand. This segment also offers respiratory illness assays, such as tests Group A strep, mycoplasma pneumonia, influenza, and pertussis; and blood chemistry products for LeadCare test kits for the detection of lead in blood. It sells products through direct sales force and independent distributors to acute care hospitals, reference laboratories, outpatient clinics, and physician office laboratories. The Life Science segment offers bulk antigens, antibodies, PCR/qPCR reagents, nucleotides, and bioresearch reagents used by in vitro diagnostic manufacturers, as well as researchers in immunological and molecular tests for human, animal, plant, and environmental applications. Meridian Bioscience, Inc. was incorporated in 1976 and is headquartered in Cincinnati, Ohio.
33.97 USD
0 (0%)
Investors Business Daily
Nov 17, 2022
After launching three new products and posting a second quarter of rising EPS growth, medical devices leader Merit Medical Systems is probing a new buy point. The post Medical Devices Stock Pumps Up Buy Point With New Innovations appeared first on Investor's Business Daily.
The Motley Fool
Oct 7, 2022
This quartet of stocks has plenty of growth ahead and is already profitable.
Zacks Investment Research
Jul 29, 2022
Meridian Bioscience (VIVO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
InvestorPlace
Jul 7, 2022
VIVO stock is a hot topic on Wall Street today, not just because Meridian Biosciences released a fiscal update, but also due to takeover news. The post Meridian Biosciences (VIVO) Stock Trending on $1.5 Billion Buyout Agreement appeared first on InvestorPlace.
Market Watch
Jul 7, 2022
Meridian Bioscience Inc. VIVO, +7.02% announced an agreement Thursday to be acquired by a consortium of South Korea-based SD Biosensor Inc. 137310, +2.08% and private equity firm SJL Partners LLC in a cash deal valued at $1.53 billion. Under terms of the deal, Meridian shareholders will receive $34.00 in cash for each Meridian share they own, representing a 1.3% premium to Wednesday's closing price of $33.55.
Seeking Alpha
Jul 5, 2022
100% technical buy signals. 8 new highs and up 15.79% in the last month.
Zacks Investment Research
Jun 20, 2022
Meridian Bioscience (VIVO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
PRNewsWire
May 23, 2022
CINCINNATI , May 23, 2022 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today its participation in the 2022 H.C. Wainwright Global Investment Conference.
The Motley Fool
May 12, 2022
These three companies are among the few that have seen their shares rise so far this year.
Benzinga
May 6, 2022
Meridian Bioscience Inc (NASDAQ: VIVO) reported a 30% increase in Q2 sales to $111.2 million, the highest in the company's history, with both segments ahead of expectations, beating the consensus of $99.54 million. Revenues from the life science division grew 32% Y/Y to $70.1 million.